Your browser is no longer supported. Please, upgrade your browser.
INSY INSYS Therapeutics, Inc. daily Stock Chart
INSYS Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.07 Insider Own0.50% Shs Outstand87.65M Perf Week-74.05%
Market Cap29.80M Forward P/E- EPS next Y-0.50 Insider Trans0.00% Shs Float26.82M Perf Month-71.43%
Income-228.10M PEG- EPS next Q-0.15 Inst Own17.80% Short Float42.31% Perf Quarter-91.79%
Sales65.80M P/S0.45 EPS this Y44.30% Inst Trans-2.70% Short Ratio3.30 Perf Half Y-93.28%
Book/sh-2.20 P/B- EPS next Y52.80% ROA-111.50% Target Price8.00 Perf Year-95.16%
Cash/sh0.96 P/C0.36 EPS next 5Y- ROE500.90% 52W Range0.14 - 11.65 Perf YTD-90.29%
Dividend- P/FCF- EPS past 5Y-34.50% ROI292.20% 52W High-97.08% Beta2.79
Dividend %- Quick Ratio0.50 Sales past 5Y-3.70% Gross Margin80.00% 52W Low139.44% ATR0.36
Employees226 Current Ratio0.50 Sales Q/Q-68.20% Oper. Margin- RSI (14)28.79 Volatility126.38% 46.33%
OptionableYes Debt/Eq- EPS Q/Q-502.40% Profit Margin- Rel Volume2.42 Prev Close0.40
ShortableNo LT Debt/Eq- EarningsJun 06 AMC Payout- Avg Volume3.44M Price0.34
Recom2.40 SMA20-58.02% SMA50-87.70% SMA200-93.75% Volume8,304,767 Change-15.00%
May-14-19Downgrade Janney Buy → Neutral
Dec-19-18Resumed Janney Buy
Mar-09-18Downgrade Piper Jaffray Neutral → Underweight
Oct-11-17Reiterated RBC Capital Mkts Outperform $14
Aug-04-17Reiterated RBC Capital Mkts Outperform $16 → $14
May-10-17Downgrade Piper Jaffray Overweight → Neutral
Dec-21-16Reiterated RBC Capital Mkts Outperform $23 → $16
Sep-22-16Reiterated RBC Capital Mkts Outperform $32 → $26
Apr-12-16Reiterated Jefferies Buy $23 → $17
Apr-11-16Reiterated Piper Jaffray Overweight $46 → $28
Feb-24-16Reiterated Jefferies Buy $36 → $23
Feb-01-16Reiterated RBC Capital Mkts Outperform $49 → $44
Mar-09-15Reiterated RBC Capital Mkts Outperform $65 → $71
Mar-04-15Reiterated RBC Capital Mkts Outperform $57 → $65
Dec-15-14Reiterated RBC Capital Mkts Outperform $53 → $57
Nov-12-14Reiterated RBC Capital Mkts Outperform $51 → $53
Nov-12-14Downgrade Oppenheimer Outperform → Perform $40
Oct-02-14Initiated RBC Capital Mkts Outperform $51
Aug-14-13Reiterated Oppenheimer Outperform $23 → $27
Jul-31-13Initiated Oppenheimer Outperform $23
Jun-12-19 12:27PM  Insys Therapeutics Bankruptcy: INSY Stock Soars on Latest News InvestorPlace +139.44%
09:39AM  Zynerba Up on Second Patent for Cannabidiol Candidate in 2019 Zacks
09:27AM  Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash Zacks
08:14AM  Insys Therapeutics' stock jumps after bankruptcy court approves 'First Day' motions MarketWatch
08:00AM  INSYS Therapeutics, Inc. Receives Court Approval of First Day Motions GlobeNewswire
Jun-11-19 06:16PM  Insys Down on Bankruptcy News Amid Increasing Legal Expenses Zacks -77.67%
09:30AM  Investors are pinning hopes on this asset again but beware, says Saxo Bank MarketWatch
Jun-10-19 05:00PM  Chandler opioid maker files for bankruptcy protection American City Business Journals -51.45%
01:30PM  Top Trending: Insys files for bankruptcy, Hudson's Bay offers to go private and more Yahoo Finance Video
01:22PM  Insys Therapeutics Bankruptcy: INSY Stock Plunges on the News InvestorPlace
12:43PM  Top Marijuana Stocks on the NASDAQ Investopedia
10:14AM  Insys Files for Bankruptcy, Overwhelmed by Costs of Opioid Suits Bloomberg
09:45AM  Insys Therapeutics Sinks After Filing for Bankruptcy
07:51AM  Insys files for bankruptcy, stock plunges toward record low MarketWatch
06:51AM  Opioid manufacturer Insys files for bankruptcy after kickback probe Reuters
06:36AM  UPDATE 4-Opioid manufacturer Insys files for bankruptcy after kickback probe Reuters
06:22AM  Opioid manufacturer Insys files for bankruptcy after kickback probe Reuters
06:20AM  Insys Therapeutics files for Chapter 11 bankruptcy Reuters
06:07AM  INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities GlobeNewswire
Jun-09-19 09:00AM  3 Marijuana Stocks I Wouldn't Touch With a 10-Foot Pole Right Now Motley Fool
Jun-06-19 03:57PM  Opioid manufacturer agrees to pay $225 million to settle corruption case MarketWatch +33.40%
10:15AM  Chandler opioid maker agrees to $225M settlement, admits to bribing docs American City Business Journals
May-29-19 07:21AM  3 Marijuana Stocks Hitting All-Time Lows Motley Fool
May-27-19 09:22AM  Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study Zacks
May-23-19 07:10AM  Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use InvestorPlace -5.57%
May-22-19 10:42AM  You Can Get Buy Signals From Short Selling InvestorPlace
May-18-19 09:50AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs Benzinga
May-17-19 03:08PM  Chandler opioid manufacturer warns it may file for bankruptcy American City Business Journals
May-13-19 01:31PM  Dow Plunges, Nasdaq Falls 3.5% After China Hikes Tariffs -73.61%
11:52AM  Why Insys Therapeutics Stock Is Crashing Today Motley Fool
10:58AM  Drugmaker Insys shares tank after saying opioid lawsuits may force it into bankruptcy CNBC
10:56AM  Opioid Maker Insys Plunges on Warning of Possible Bankruptcy Bloomberg
09:55AM  Opioid Maker Insys Sinks After Saying It May Be Forced to File Bankruptcy
09:35AM  Insys stock plunges 70% after Friday disclosure of company's woes MarketWatch
06:06AM  Investing $1,000 Into This Marijuana Stock in 2016 Would Leave You With Pennies on the Dollar Today Motley Fool
May-11-19 12:23AM  Insys says it may be forced to file for bankruptcy due to litigation cash crunch Reuters
May-10-19 09:46PM  Insys says it may be forced to file for bankruptcy due to litigation cash crunch Reuters -9.77%
08:25PM  Insys Therapeutics (INSY) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:17PM  Insys Therapeutics: 1Q Earnings Snapshot Associated Press
07:05PM  INSYS Therapeutics Reports First Quarter 2019 Results GlobeNewswire
May-03-19 10:00AM  Insys Executives Found Guilty Of Bribing Doctors In Fentanyl Case Market Exclusive
07:28AM  Insys execs found guilty of bribing doctors to prescribe highly addictive opioid CBS News Videos
May-02-19 11:39PM  Insys founder convicted of bribing doctors to push highly addictive fentanyl spray MarketWatch
06:10PM  Founder, execs of drug company guilty in conspiracy that fed opioid crisis Reuters
05:30PM  Insyss John Kapoor Is First CEO Convicted of Opioid Racketeering Bloomberg
04:21PM  Founder, executives of drug company guilty in conspiracy that fed opioid crisis Reuters
04:08PM  Insys Therapeutics Founder Convicted in Opioid Bribery Scheme: Report
03:08PM  Insys Therapeutics founder, former executives found guilty in criminal fentanyl bribery case CNBC
02:05PM  Verdict reached in U.S. opioid bribe scheme trial of drug executives Reuters
Apr-30-19 08:00PM  Troubled Chandler pharma company shares compensation data for top execs American City Business Journals
Apr-23-19 10:00PM  Chandler drugmaker gives big bonuses to new CEO, other C-suite execs American City Business Journals
Apr-15-19 01:41PM  Insys Therapeutics Declines After Replacing CEO Saeed Motahari
08:30AM  INSYS Therapeutics Implements Leadership Changes GlobeNewswire
Apr-05-19 08:21AM  3 Marijuana Stocks to Avoid Like the Plague in April Motley Fool
Apr-04-19 06:14PM  Jurors hear final arguments in opioid bribe scheme case Associated Press
04:41PM  Drug company founder, execs exploited patients to sell opioid: U.S. prosecutor Reuters
04:13PM  Drug company founder, execs exploited patients to sell opioid: U.S. prosecutor Reuters
02:02PM  Drug company founder put 'profits over patients' to push opioid: U.S. prosecutor Reuters
08:21AM  These Worst-Performing Pot Stocks Fell at Least 20% in March Motley Fool
Apr-02-19 08:40AM  Implied Volatility Surging for INSYS Therapeutics (INSY) Stock Options Zacks
Mar-29-19 05:45PM  Insys Therapeutics (INSY) Outpaces Stock Market Gains: What You Should Know Zacks
Mar-25-19 06:00AM  INSYS Therapeutics to Present Poster of Pharmacokinetic Study of Naloxone Novel Nasal Spray at The College on Problems of Drug Dependence Annual Scientific Meeting GlobeNewswire
Mar-21-19 05:50PM  Insys Therapeutics (INSY) Outpaces Stock Market Gains: What You Should Know Zacks
Mar-20-19 09:21AM  3 Pot Stocks With Skyrocketing Short Interest Motley Fool
Mar-14-19 11:01AM  Insys Plunges on Auditor's Concern About Insufficient Funds Zacks
Mar-13-19 07:56PM  Edited Transcript of INSY earnings conference call or presentation 7-Mar-19 10:00pm GMT Thomson Reuters StreetEvents -25.18%
04:38PM  Why Express, Roku, and Insys Therapeutics Slumped Today Motley Fool
04:30PM  Why Insys Therapeutics Shares Crashed Today Motley Fool
03:38PM  Insys stock drops 27% after auditor questions company's viability MarketWatch
01:49PM  Insys Plunges as Opioid Maker Warns That It May Run Out of Cash Bloomberg
11:35AM  Insys Therapeutics' auditor raises going concern doubts, shares drop Reuters
10:47AM  Insys Therapeutics' auditor raises going concern doubts, shares drop Reuters
07:48AM  Insys Therapeutics Inc (INSY) Files 10-K for the Fiscal Year Ended on December 31, 2018
Mar-08-19 01:29PM  Insys Therapeutics (INSY) Q4 2018 Earnings Conference Call Transcript Motley Fool
10:38AM  Analysts Positive On Insys Ahead Of 2019 Pipeline Catalysts Benzinga
Mar-07-19 06:17PM  Insys says Lazard hired to advise on options, in talks to divest Subsys Reuters
04:15PM  INSYS Therapeutics Reports Fourth Quarter and Full Year 2018 Results GlobeNewswire
Mar-06-19 04:15PM  INSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7 GlobeNewswire
11:30AM  Non-Opioid Treatment Cos. for Investors in Wake of Purdue Pharma News ACCESSWIRE
09:15AM  Stocks Get Stuck Waiting for Trade Deal Zacks
Mar-05-19 07:21AM  3 Marijuana Stocks to Avoid Like the Plague in March Motley Fool
Mar-04-19 08:21AM  February's 5 Best Marijuana Stocks Motley Fool
06:00AM  5 Best Marijuana Stocks in February -- Are They Buys Now? Motley Fool
Feb-27-19 03:00PM  Four Marijuana Stocks Seeing New Highs On Wednesday ACCESSWIRE
Feb-26-19 07:45AM  Insys Therapeutics Presents Study Results Showing Rapid Absorption Of Epinephrine Market Exclusive
Feb-25-19 03:50PM  Watch These 4 Marijuana Stocks On Monday (2/25/19) ACCESSWIRE
06:00AM  INSYS Therapeutics Presented Poster of Initial Pharmacokinetic Study of Epinephrine Nasal Spray for the Emergency Treatment of Allergic Reactions (Type I) including Anaphylaxis at American Academy of Allergy, Asthma and Immunology Annual Meeting GlobeNewswire
Feb-23-19 08:54AM  FDA opioids adviser: 'One thing is clear' about the ongoing crisis Yahoo Finance
Feb-20-19 02:30PM  Four Marijuana Stocks Looking To Raise The Bar On Wednesday (2/20/19) ACCESSWIRE
Feb-19-19 01:55PM  4 Marijuana Stocks Gaining Speed On Tuesday (2/19/19) ACCESSWIRE +13.51%
Feb-15-19 03:19PM  Opioid maker used rap video to push powerful painkiller Associated Press
12:59PM  Drug company used rap video to push for higher doses, sales Associated Press
09:04AM  Worst Performing Cannabis Stocks in 2018 Investopedia
Feb-14-19 07:32AM  Insys executives used rap video to push sales of potentially lethal opioid CBS News Videos
Feb-08-19 02:35PM  4 Marijuana Stocks Looking To Pick Up Speed This Month ACCESSWIRE +7.30%
Feb-07-19 11:44AM  Zynerba Stock Is Marijuana-Adjacent Play Worth a Look InvestorPlace
10:00AM  Cannabis Plays Going Higher ACCESSWIRE
Feb-05-19 11:20AM  4 Marijuana Stocks Looking to Set the Standard ACCESSWIRE +9.82%
10:00AM  Playing the Big Cannabis Rebound ACCESSWIRE
08:51AM  The Only 2 Pot Stocks to Fall in January Motley Fool
Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.